Evaluation of an Automated System to Culture Metastatic Patient Circulating Tumor Cells in Embryonated Chicken Eggs (in Ovo Culture)

Plain-language summary

This study evaluates an automated system that cultures circulating tumor cells from the blood of patients with metastatic cancer in embryonated chicken eggs. It enrolled patients over 18 with histologically confirmed metastatic cancers such as prostate, breast, lung, ovarian, colorectal or gastric cancer. It was a study without a phase and has been completed.

The summary above is a plain-language rendering of the official record. The original English title is shown for reference.

Trial details

Phase

Not Applicable

Status

Completed

Sponsor

Hospices Civils de Lyon

Intervention

Patient sampling.

Start date

2/14/2023

Estimated completion

2/14/2025

Countries

France

Related genes

Locations

• Pierre-Bénite, France
• Pierre-Bénite, France

Eligibility criteria

Criteria are reproduced from the ClinicalTrials.gov record in the original English. Only the trial team can determine eligibility.

* Inclusion Criteria for all cohorts \* :

  * Age \> 18
  * Signed consent
  * Inclusion criteria for the "Prostate" cohort:
  * prostate adenocarcinoma histologically proven
  * metastatic situation
  * at least 2 metastatic sites
  * Evolutionary disease that requires a new treatment
  * Inclusion criteria for the "Breast" cohort:
  * HER2+ or RH+ breast adenocarcinoma histologically proven
  * metastatic situation
  * at least 2 metastatic sites
  * Evolutionary disease that requires a new treatment
  * Inclusion criteria for the "Lung" cohort:
  * Non Small Lung cancer histologically proven
  * metastatic situation
  * at least 2 metastatic sites
  * Evolutionary disease that requires a new treatment
  * Inclusion criteria for "Ovarian" cohort:
  * Ovarian cancer histologically proven
  * Presence of peritoneal carcinomatosis (stage IIIC or IV); with or without presence of peritoneal fluid
  * Inclusion criteria for "Colo-Rectal" cohort:
  * Colo-rectal cancer histologically proven
  * Presence of peritoneal carcinomatosis, with or without presence of peritoneal fluid
  * Evolutionary disease that requires a new treatment
  * Inclusion criteria for "Gastric" cohort:
  * Gastric cancer histologically proven
  * Presence of peritoneal carcinomatosis, with or without presence of peritoneal fluid
* Exclusion Criteria for all cohorts \* :

  * Weight \<50kg
  * Parallel participation in a doubled blinded study
  * Brain or ganglionary metastasis only